TrialThe Lancet. Infectious diseases2024

Safety and durable immunogenicity of the TV005 tetravalent dengue vaccine, across serotypes and age groups, in dengue-endemic Bangladesh: a randomised, controlled trial.

Mary-Claire R Walsh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.